arrow
S

Susan Ellard

british columbia cancer agency
H指数:35
被引数:8,539

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
2024-11-010
PRE
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study
2023-11-081
OA
The future of HER2-positive breast cancer patients might be written in miRNAs: An exploratory analysis from the NeoALTTO study
2022-02-150
PRE
The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32
2020-06-0420
OAAI
Safety and dose modification for patients receiving niraparib

接受尼拉帕利的患者的安全性和剂量调整

2018-08-01145
OAAI
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

拉帕替尼联合foretinib,c-met,AXL和血管内皮生长因子受体抑制剂治疗人类表皮生长因子受体2 (HER-2) 阳性转移性乳腺癌的I期研究

2017-05-0228
OAAI
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
2016-04-2646
PREAI
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy na⟨ve castration-resistant prostate cancer

凡德他尼 (ZD6474) 联合比卡鲁胺与单独比卡鲁胺治疗化疗无效去势抵抗性前列腺癌患者的随机II期疗效和安全性研究

2014-03-2826
PREAI